<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04234594</url>
  </required_header>
  <id_info>
    <org_study_id>QL1203-002</org_study_id>
    <nct_id>NCT04234594</nct_id>
  </id_info>
  <brief_title>Comparing the Pharmacokinetic and Safety of QL1203 and Vectibix® in Healthy Males.</brief_title>
  <official_title>A Randomized, Double-blind and Single-dose Study to Compare the Pharmacokinetic and Safety of QL1203 and Vectibix® in Healthy Male Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qilu Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qilu Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind and parallel group study to compare the pharmacokinetic and safety
      of QL1203 and Vectibix® in healthy males.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I,single center, randomized, double-blind，single-dose and parallel group
      clinical trial . The primary objective is to assess the pharmacokinetic similarity of of
      QL1203 or Vectibix® in healthy male volunteers. The secondary objective are to assess the
      Clinical safety and immunogenicity similarity of QL1203 or Vectibix® in healthy male
      volunteers&quot;.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC0-t )</measure>
    <time_frame>36 days</time_frame>
    <description>Area under the plasma concentration-time curve (AUC0-t ) from 0 o'clock to the last measurable concentration acquisition time t.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Healthy Males</condition>
  <arm_group>
    <arm_group_label>QL1203</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants only receive QL1203, 6mg/kg on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vectibix®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants only received Vectibix®，6 mg/kg on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QL1203</intervention_name>
    <description>6 mg/kg intravenous (IV) infusion only once，on the first day.</description>
    <arm_group_label>QL1203</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vectibix®</intervention_name>
    <description>6 mg/kg intravenous (IV) infusion only once，on the first day.</description>
    <arm_group_label>Vectibix®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects sign the informed consent form and fully understand purpose, nature, process
             and possible adverse reactions of the study, and are able to complete the study
             according to the study plan requirements.

          -  Male,18 years to 65 years of age.

          -  Weight ≧50.0 kg; body mass index (BMI) in the range of 19.0～ 26.0 kg / m^2.

          -  Subjects have no history of chronic diseases or serious diseases such as
             cardiovascular, liver, kidney, respiratory, blood and lymph, endocrine, immune,
             psychiatric, nervous, gastrointestinal system diseases and the general health is good.

          -  Clinical laboratory examination, chest X-ray, abdominal B-ultrasound,
             electrocardiogram, physical examination, vital signs and various examinations are
             normal or abnormal without clinical significance.

        Exclusion Criteria:

          -  Subjects have used any biological product within 3 months prior to receiving the study
             drug, or have used any monoclonal antibody drugs within 9 months.

          -  Subjects have anallergic history to study drug or any drug component; or persons with
             allergic history to two or more drugs and food.

          -  Subjects have a history of interstitial lung disease.

          -  Subjects have a history of keratitis or long-term wearing of contact lens.

          -  Subjects have used any prescription drugs, over-the-counter medicines, Chinese herbal
             medicines, and vitamins within 2 weeks before receiving the study drugs.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weiwei Ouyang, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Hospital of Guizhou Province</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shunjiang Yu, CMO</last_name>
    <phone>0531-83129659</phone>
    <email>shunjiang.yu@qilu-pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guizhou Cancer Hospital</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <zip>550000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weiwei Ouyang, Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Kunming Medical University</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Wu, Professor</last_name>
    </contact>
    <contact_backup>
      <last_name>Li He, Professor</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 16, 2020</study_first_submitted>
  <study_first_submitted_qc>January 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 21, 2020</study_first_posted>
  <last_update_submitted>May 17, 2020</last_update_submitted>
  <last_update_submitted_qc>May 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Panitumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

